Skip to content

Precision Neuromodulation and Cognitive Remodeling:hippocampal functional connectivity–guided dual-target Theta Burst Stimulation for the treatment of depression

Precision Neuromodulation and Cognitive Remodeling:hippocampal functional connectivity–guided dual-target Theta Burst Stimulation for the treatment of depression

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600118728
Enrollment
Unknown
Registered
2026-02-10
Start date
2026-02-16
Completion date
Unknown
Last updated
2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

depressive with cognitive impairment

Interventions

Traditional TBS Group:Left DLPFC:iTBS
Right DLPFC:cTBS
Individualized TBS group:Left DLPFC:iTBS
Parietal lobe target :iTBS

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-60 years old; 2. Meet the diagnostic criteria for depressive disorder in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5); 3. Hamilton Depression Scale 17-item version (HAMD-17) score >= 17 points; 4. If the medication has never been taken at the time of enrollment, the medication will not be added during,If antidepressants have been taken in the past, drug washout is required for 4 weeks, the treatment period, If you are taking medication, take medication regularly for at least 4 weeks, and the medication remains unchanged during treatment; 5. Be able to cooperate with clinical assessment, magnetic resonance scanning, near-infrared brain function imaging and neuromodulation; 6. Patients voluntarily participate in the study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Current or previous diagnosis of bipolar disorder, schizophrenia or other psychotic disorders, schizoaffective disorder, autism or autism spectrum disorder, etc. 2. Neurological diseases such as craniocerebral organic diseases, cranial trauma, refractory epilepsy, and dementia; 3. Patients with serious physical diseases who are not suitable for neuromodulation therapy as judged by the investigator; 4. History of suicide attempt within 3 months; 5. History of substance dependence or substance abuse; 6. Other contraindications to neuromodulation or near-infrared brain function imaging or MRI; 7. Women who are pregnant or are trying to conceive recently.

Design outcomes

Primary

MeasureTime frame
Hamilton Depression Scale, HAMD;

Secondary

MeasureTime frame
Sheehan Disability Scale;Self-rating depression scale;Clinical Global Impressions- Improvement;CANTAB-PRM;Self-Rating Anxiety Scale;Wechsler Memory Scale;CANTAB-SSP;Stroop task: Color-word interference effect time;Hamilton Anxiety Scale, HAMA;Columbia-Suicide Severity Rating Scale, C-SSRS ;Pittsburgh sleep quality index, PSQI ;CANTAB-SWM;

Countries

China

Contacts

Public ContactBin Li

West China Hospital of Sichuan University

libinjia@163.com+86 28 85422633

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 19, 2026